Medicine

Peptides as Homing Devices on a New Front in Cancer Care

Some of the most promising uses of peptides in oncology are not about killing cancer directly, but about finding it, marking it and training the immune system to notice it.

Cover illustration for Peptides as Homing Devices on a New Front in Cancer Care

Smart delivery rather than brute force

Traditional chemotherapy hits fast-dividing cells everywhere. Peptides open a more targeted option, because many of them are exquisitely good at binding one specific receptor. If a tumour has far more of that receptor than healthy tissue, a peptide can act like a key looking for the right lock.

Idea 1 Peptide plus radiation

In peptide receptor radionuclide therapy (PRRT), a peptide that binds a receptor common on certain neuroendocrine tumours is attached to a radioactive atom. The peptide carries the radiation to the tumour cells and spares much of the surrounding tissue. A therapy of this kind, based on a somatostatin-like peptide, has been approved for certain neuroendocrine tumours, and the same principle is used for imaging.

Idea 2 Peptide plus drug

Researchers also link peptides to chemotherapy drugs, forming peptide-drug conjugates. The goal is a higher dose where it matters and a lower dose elsewhere. Several candidates are in clinical trials, with mixed results so far.

Idea 3 Teaching the immune system

Cancer cells display small fragments of their own proteins, peptides, on their surface. Some of these fragments, especially those created by mutations unique to a tumour (neoantigens), look foreign to the immune system.

Peptide vaccines aim to show the immune system those fragments in a way that provokes a response. Personalised approaches sequence a patient's tumour, predict which mutated peptides are likely to be recognised, and build a vaccine from them. Early clinical trials, often combined with immune checkpoint drugs, have produced encouraging signals in some cancers, but this is still an investigational field.

What to keep in mind

  • Early does not mean proven. Small trials can show an impressive response in a handful of patients and still fail in larger studies.
  • Context matters. A therapy that works for one tumour type, selected by a biomarker, may do nothing in another.
  • Side effects are real. Radiation, immune activation and conjugated drugs each carry their own risks.

A word of caution about online claims

Be sceptical of any product claiming a peptide "targets" or "dissolves" cancer. Real targeted therapies are made under strict manufacturing rules, selected through diagnostic tests and given by specialised teams.

The takeaway

Peptides are well suited to finding and marking cells, which makes them valuable in oncology. The genuine progress is slow, carefully tested and delivered through specialist care.

Sources

  1. DailyMed: Lutathera label (initial US approval 2018)
  2. PubMed, PMID 28076709: Strosberg et al. 2017, NETTER-1 trial of 177Lu-Dotatate (N Engl J Med)
  3. PubMed, PMID 28678778: Ott et al. 2017, personal neoantigen vaccine in melanoma (Nature)
Educational only. This article does not replace advice from a doctor or pharmacist. Read the full disclaimer.
Peptide City Editorial

We explain how peptides work and what the evidence shows. Amounts are reported as study or label data, never as advice, and we never name sellers. How articles are checked.